Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Intensive Care Medicine
Erschienen in: Intensive Care Medicine 2/2020

29.01.2020 | Narrative Review

Antimicrobial-associated harm in critical care: a narrative review

Erschienen in: Intensive Care Medicine | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

The belief that, for the individual patient, the benefit of prompt and continued use of antimicrobials outweighs any potential harm is a significant barrier to improved stewardship of these vital agents. Antimicrobial stewardship may be perceived as utilitarian rationing, seeking to preserve the availability of effective antimicrobials by limiting the development of resistance in a manner which could conflict with the immediate treatment of the patient in need. This view does not account for the growing evidence of antimicrobial-associated harm to individual patients. This review sets out the evidence for antimicrobial-associated harm and how this should be balanced with the need for prompt and appropriate therapy in infection. It describes the mechanisms by which antimicrobials may harm patients including: mitochondrial toxicity; immune cell toxicity; adverse drug reactions; selection of resistant organisms within a given patient; and disruption of the microbiome. Finally, the article indicates how the harms of antimicrobials may be mitigated and identifies areas for research and development in this field.
Literatur
1.
Vincent J-L, Rello J, Marshall J et al (2009) International study of the prevalence and outcomes of infection in intensive care units. JAMA 302(21):2323–2329PubMed
2.
Kollef MH (2000) Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 31:S131–S138PubMed
3.
Kumar A, Roberts D, Wood KE et al (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 34(6):1589–1596PubMed
4.
de Jong E, van Oers JA, Beishuizen A, Infectious PVTL (2016) Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis 16(7):819–827
5.
Kett DH, Cano E, Quartin AA et al (2011) Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care: an observational, multicentre cohort study. Lancet Infect Dis 11(3):181–189PubMed
6.
Cotten CM, Taylor S, Stoll B et al (2009) Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics 123(1):58–66PubMed
7.
Seymour CW, Gesten F, Prescott HC et al (2017) Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 376(23):2235–2244PubMedPubMedCentral
8.
Bloos F, Rüddel H, Thomas-Rüddel D et al (2017) Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: a cluster randomized trial. Intensive Care Med 43(11):1602–1612PubMed
9.
Rhodes A, Evans LE, Alhazzani W et al (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304–377PubMed
10.
Bloos F, Thomas-Rüddel D, Rüddel H et al (2014) Impact of compliance with infection management guidelines on outcome in patients with severe sepsis: a prospective observational multi-center study. Crit Care 18(2):R42PubMedPubMedCentral
11.
Wachter RM, Flanders SA, Fee C, Pronovost PJ (2008) Public reporting of antibiotic timing in patients with pneumonia: lessons from a flawed performance measure. Ann Intern Med 149(1):29–32PubMed
12.
Hranjec T, Rosenberger LH, Swenson B et al (2012) Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study. Lancet Infect Dis 12(10):774–780PubMedPubMedCentral
13.
Prescott HC, Iwashyna TJ (2019) Improving sepsis treatment by embracing diagnostic uncertainty. Annals ATS 16(4):426–429
14.
De Waele JJ (2010) Early source control in sepsis. Langenbecks Arch Surg 395(5):489–494PubMed
15.
Fagon JY, Chastre J, Wolff M et al (2000) Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 132(8):621–630PubMed
16.
Canadian Critical Care Trials Group (2006) A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 355(25):2619–2630
17.
Ruiz M, Torres A, Ewig S et al (2000) Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. Am J Respir Crit Care Med 162(1):119–125PubMed
18.
Bouadma L, Luyt C-E, Tubach F et al (2010) Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375(9713):463–474PubMed
19.
Onakpoya IJ, Walker AS, Tan PS et al (2018) Overview of systematic reviews assessing the evidence for shorter versus longer duration antibiotic treatment for bacterial infections in secondary care. PLoS ONE 13(3):e0194858PubMedPubMedCentral
20.
Llewelyn MJ, Fitzpatrick JM, Darwin E et al (2017) The antibiotic course has had its day. BMJ 358:j3418PubMed
21.
Uranga A, España PP, Bilbao A et al (2016) Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med 176(9):1257–1265PubMed
22.
Capellier G, Mockly H, Charpentier C, et al. (2012) Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment. Spellberg B, ed. PLoS One 7(8):e41290–12
23.
Chastre J, Wolff M, Fagon J-Y et al (2003) Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290(19):2588–2598PubMed
24.
Kollef MH, Chastre J, Clavel M et al (2012) A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 16(6):R218PubMedPubMedCentral
25.
Scawn N, Saul D, Pathak D et al (2012) A pilot randomised controlled trial in intensive care patients comparing 7 days’ treatment with empirical antibiotics with 2 days’ treatment for hospital-acquired infection of unknown origin. Health Technol Assess 16(36):1–94
26.
Leone M, Bechis C, Baumstarck K et al (2014) De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive Care Med 40(10):1399–1408PubMed
27.
Carvalho DS, Andrade RFS, Pinho STR et al (2015) What are the evolutionary origins of mitochondria? A complex network approach. PLoS ONE 10(9):e0134988–e135021PubMedPubMedCentral
28.
Singer M (2013) The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence 5(1):66–72PubMedPubMedCentral
29.
Kalghatgi S, Spina CS, Costello JC et al (2013) Bactericidal antibiotics induce mitochondrial dysfunction and oxidative damage in mammalian cells. Science Trans Med 5(192):192
30.
Brealey D, Brand M, Hargreaves I et al (2002) Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 360(9328):219–223PubMed
31.
Carré JE, Orban J-C, Re L et al (2010) Survival in critical illness is associated with early activation of mitochondrial biogenesis. Am J Respir Crit Care Med 182(6):745–751PubMedPubMedCentral
32.
Galley HF (2011) Oxidative stress and mitochondrial dysfunction in sepsis. Br J Anaesth 107(1):57–64PubMed
33.
34.
Dröse S, Brandt U (2008) The mechanism of mitochondrial superoxide production by the cytochrome bc1 complex. J Biol Chem 283(31):21649–21654PubMed
35.
Tune BM, Hsu CY (1990) The renal mitochondrial toxicity of beta-lactam antibiotics: in vitro effects of cephaloglycin and imipenem. J Am Soc Nephrol 1(5):815–821PubMed
36.
Duewelhenke N, Krut O, Eysel P (2007) Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines. Antimicrob Agents Chemother 51(1):54–63PubMed
37.
Lawrence JW, Claire DC, Weissig V, Rowe TC (1996) Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells. Mol Pharmacol 50(5):1178–1188PubMed
38.
Mantzarlis K, Tsolaki V, Zakynthinos E (2017) Role of oxidative stress and mitochondrial dysfunction in sepsis and potential therapies. Ox Med Cell Long 2017(7):1–10
39.
Manzanares W, Lemieux M, Elke G, Langlois PL, Bloos F, Heyland DK (2016) High-dose intravenous selenium does not improve clinical outcomes in the critically ill: a systematic review and meta-analysis. Crit Care 20:356PubMedPubMedCentral
40.
Morris AC, Datta D, Shankar-Hari M et al (2018) Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study. Intensive Care Med 44(5):627–635
41.
Cheng S-C, Scicluna BP, Arts RJW et al (2016) Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nat Immunol 17(4):406–413PubMed
42.
Hauser WE, Remington JS (1982) Effect of antibiotics on the immune response. Am J Med 72(5):711–716PubMed
43.
Garaude J, Acín-Pérez R, Martínez-Cano S et al (2016) Mitochondrial respiratory-chain adaptations in macrophages contribute to antibacterial host defense. Nat Immunol 17(9):1037–1045PubMedPubMedCentral
44.
Yang JH, Bhargava P, McCloskey D, Mao N, Palsson BO, Collins JJ (2017) Antibiotic-induced changes to the host metabolic environment inhibit drug efficacy and alter immune function. Cell Host Microbe 22(6):757–765.e3PubMedPubMedCentral
45.
Zhong Z, Liang S, Sanchez-Lopez E et al (2018) New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature 560(7717):198–203PubMedPubMedCentral
46.
Kelly B, Tannahill GM, Murphy MP, O'Neill LAJ (2015) Metformin inhibits the production of reactive oxygen species from NADH: ubiquinone oxidoreductase to limit induction of interleukin-1β (IL-1β) and boosts interleukin-10 (IL-10) in lipopolysaccharide (LPS)-activated macrophages. J Biol Chem 290(33):20348–20359PubMedPubMedCentral
47.
Martínez-García JJ, Martínez-Banaclocha H, Angosto-Bazarra D et al (2019) P2X7 receptor induces mitochondrial failure in monocytes and compromises NLRP3 inflammasome activation during sepsis. Nature Comms 10(1):2711
48.
Granowitz EV, Brown RB (2008) Antibiotic adverse reactions and drug interactions. Crit Care Clin 24(2):421–442PubMed
49.
Jager NGL, van Hest RM, Lipman J, Taccone FS, Roberts JA (2016) Therapeutic drug monitoring of anti-infective agents in critically ill patients. Expert Rev Clin Pharm 9(7):961–979
50.
Bhattacharyya S, Darby RR, Raibagkar P, Gonzalez Castro LN, Berkowitz AL (2016) Antibiotic-associated encephalopathy. Neurology 86(10):963–971PubMed
51.
Cornett E, Novitch MB, Kaye AD et al (2017) Macrolide and fluoroquinolone mediated cardiac arrhythmias: clinical considerations and comprehensive review. Postgrad Med 129(7):715–724PubMed
52.
Harper NJN, Cook TM, Garcez T et al (2018) Anaesthesia, surgery, and life-threatening allergic reactions: epidemiology and clinical features of perioperative anaphylaxis in the 6th National Audit Project (NAP6). Br J Anaes 121(1):159–171
53.
Kanji S, Chant C (2010) Allergic and hypersensitivity reactions in the intensive care unit. Critical Care Med 38:S162–S168
54.
Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ (2019) Antibiotic allergy. Lancet 393(10167):183–198PubMed
55.
Blumenthal KG, Ryan EE, Li Y, Lee H, Kuhlen JL, Shenoy ES (2017) The impact of a reported penicillin allergy on surgical site infection risk. Clin Infect Dis 66(3):329–336PubMedCentral
56.
57.
58.
Neidell MJ, Cohen B, Furuya Y et al (2012) Costs of healthcare- and community-associated infections with antimicrobial-resistant versus antimicrobial-susceptible organisms. Clin Infect Dis 55(6):807–815PubMedPubMedCentral
59.
Apellaniz G, Valdés M, Perez R et al (1991) Comparison of the effectiveness of various antibiotics in the treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis. J Chemother 3(2):91–97PubMed
60.
Tabah A, Koulenti D, Laupland K et al (2012) Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med 38(12):1930–1945PubMed
61.
62.
Munoz-Price LS, Poirel L, Bonomo RA et al (2013) Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13(9):785–796PubMedPubMedCentral
63.
Marchaim D, Chopra T, Bhargava A et al (2015) recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship. Infect Control Hosp Epidemiol 33(8):817–830
64.
Armand-Lefèvre L, Angebault C, Barbier F et al (2013) Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 57(3):1488–1495PubMedPubMedCentral
65.
Ang H, Sun X (2018) Risk factors for multidrug-resistant Gram-negative bacteria infection in intensive care units: a meta-analysis. Int J Nurs Pract 24(4):e12644–e12713PubMed
66.
Raman K, Nailor MD, Nicolau DP, Aslanzadeh J, Nadeau M, Kuti JL (2013) Early antibiotic discontinuation in patients with clinically suspected ventilator-associated pneumonia and negative quantitative bronchoscopy cultures. Crit Care Med 41(7):1656–1663PubMed
67.
Ewig S, Torres A, El-Ebiary M, et al. (1999) Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator-associated pneumonia. Am J Respir Crit Care Med 159(1): 188–198PubMed
68.
Trouillet JL, Vuagnat A, Combes A, Kassis N, Chastre J, Gibert C (2002) Pseudomonas aeruginosa ventilator-associated pneumonia: comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 34(8):1047–1054PubMed
69.
Bootsma M, Bonten M, Nijssen S, Fluit A, Diekmann O (2007) An Algorithm to estimate the importance of bacterial acquisition routes in hospital settings. Am J Epidemiol 166(7):841–851PubMed
70.
Derde LPG, Cooper BS, Goossens H et al (2014) Interventions to reduce colonisation and transmission of antimicrobial-resistant bacteria in intensive care units: an interrupted time series study and cluster randomised trial. Lancet Infect Dis. 14(1):31–39PubMedPubMedCentral
71.
Wischmeyer PE, McDonald D, Knight R (2016) Role of the microbiome, probiotics, and “dysbiosis therapy” in critical illness. Curr Opin Crit Care 22(4):347–353PubMedPubMedCentral
72.
Zaborin A, Smith D, Garfield K, et al. (2014) Membership and behavior of ultra-low-diversity pathogen communities present in the gut of humans during prolonged critical illness Clemente J, Dominguez Bello MG, eds. mBio 5(5): 01361–14
73.
Baron SA, Diene SM, Rolain JM (2018) Human microbiomes and antibiotic resistance. Human Microbiome J 10:43–52
74.
75.
Saltzman ET, Palacios T, Thomsen M, Vitetta L (2018) Intestinal microbiome shifts, dysbiosis, inflammation, and non-alcoholic fatty liver disease. Front Microbiol 9:307–311
76.
McDonald D, Ackermann G, Khailova L, et al. (2016) Extreme dysbiosis of the microbiome in critical illness. Green Tringe S, ed. mSphere 1(4):207–6
77.
Alagna L, Bandera A, Patruno A, Muscatello A, Citerio G, Gori A (2019) Microbiota in ICU, not only a gut problem. Intensive Care Med 45(5):733–737PubMed
78.
Yeh A, Rogers MB, Firek B, Neal MD, Zuckerbraun BS, Morowitz MJ (2016) Dysbiosis across multiple body sites in critically ill adult surgical patients. Shock 46(6):649–654PubMed
79.
Zakharkina T, Martin-Loeches I, Matamoros S et al (2017) The dynamics of the pulmonary microbiome during mechanical ventilation in the intensive care unit and the association with occurrence of pneumonia. Thorax 72(9):803–810PubMed
80.
Lankelma JM, Vught LA, Belzer C et al (2016) Critically ill patients demonstrate large interpersonal variation in intestinal microbiota dysregulation: a pilot study. Intensive Care Med 43(1):59–68PubMedPubMedCentral
81.
Pettigrew MM, Gent JF, Kong Y et al (2018) Gastrointestinal microbiota disruption and risk of colonization with carbapenem-resistant Pseudomonas aeruginosa in Intensive Care Unit Patients. Clin Infect Dis 69(4):604–613PubMedCentral
82.
Otani S, Chihade DB, Coopersmith CM (2019) Critical illness and the role of the microbiome. Acute Med Surg 6(2):91–94PubMed
83.
Dickson RP, Singer BH, Newstead MW et al (2016) Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. Nat Microbiol 1(10):16113PubMedPubMedCentral
84.
Ravi A, Halstead FD, Bamford A et al (2019) Loss of microbial diversity and pathogen domination of the gut microbiota in critically ill patients. bioRxiv 9:151–236
85.
Hankovszky P, Társy D, Öveges N, Molnár Z (2015) Invasive Candida infections in the ICU: diagnosis and therapy. J Crit Care Med 1(4):129–139
86.
Kigerl KA, Hall JCE, Wang L, Mo X, Yu Z, Popovich PG (2016) Gut dysbiosis impairs recovery after spinal cord injury. J Exp Med 213(12):2603–2620PubMedPubMedCentral
87.
Robak OH, Heimesaat MM, Kruglov AA et al (2018) Antibiotic treatment–induced secondary IgA deficiency enhances susceptibility to Pseudomonas aeruginosa pneumonia. J Clin Invest 128(8):3535–3545PubMedPubMedCentral
88.
Ichinohe T, Pang IK, Kumamoto Y et al (2011) Microbiota regulates immune defense against respiratory tract influenza A virus infection. Proc Natl Acad Sci USA 108(13):5354–5359PubMedPubMedCentral
89.
Johanesen P, Mackin K, Hutton M et al (2015) Disruption of the gut microbiome: clostridium difficile infection and the threat of antibiotic resistance. Genes 6(4):1347–1360PubMedPubMedCentral
90.
Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 41(9): 835–843
91.
Staley C, Kelly CR, Brandt LJ, Khoruts A, Sadowsky MJ (2016) Complete microbiota engraftment is not essential for recovery from recurrent Clostridium difficile infection following fecal microbiota transplantation. mBio 7(6):2074–2079
92.
93.
Karanika S, Paudel S, Grigoras C, Kalbasi A, Mylonakis E (2016) Systematic review and meta-analysis of clinical and economic outcomes from the implementation of hospital-based antimicrobial stewardship programs. Antimicrob Agents Chemother 60(8):4840–4852PubMedPubMedCentral
94.
95.
Morris AC, Hay AW, Swann DG et al (2011) Reducing ventilator-associated pneumonia in intensive care: Impact of implementing a care bundle. Crit Care Med 39(10):2218–2224PubMed
96.
Gadsby NJ, Russell CD, McHugh MP et al (2016) Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis 62(7):817–823PubMed
97.
Chiu CY, Miller SA (2019) Clinical metagenomics. Nature Rev Genet 20(6):341–355PubMed
98.
Weng H, Li J-G, Mao Z et al (2017) Probiotics for preventing ventilator-associated pneumonia in mechanically ventilated patients: a meta-analysis with trial sequential analysis. Front Pharmacol 8:S17–S36
99.
Wheeler KE, Cook DJ, Mehta S et al (2016) Use of probiotics to prevent ventilator-associated pneumonia: a survey of pharmacists' attitudes. J Crit Care 31(1):221–226PubMed
100.
De Filipp Z, Bloom PP, Torres Soto M et al (2019) Drug-resistant E coli bacteremia transmitted by fecal microbiota transplant. N Engl J Med 381(21):2043–2050
101.
Yelin I, Flett KB, Merakou C et al (2019) Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nat Med 25:1728–1732PubMedPubMedCentral
Metadaten
Titel
Antimicrobial-associated harm in critical care: a narrative review
Publikationsdatum
29.01.2020
Erschienen in
Intensive Care Medicine / Ausgabe 2/2020
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-020-05929-3

Weitere Artikel der Ausgabe 2/2020

Intensive Care Medicine 2/2020 Zur Ausgabe

Narrative Review

Treatment of Ebola-related critical illness

Editorial

Clinical management of sepsis can be improved by artificial intelligence: yes

Editorial

The zero-VAP sophistry and controversies surrounding prevention of ventilator-associated pneumonia

Conference Reports and Expert Panel

Bloodstream infections in critically ill patients: an expert statement

Understanding the Disease

Understanding resistance in enterococcal infections

Narrative Review

Management of HIV-infected patients in the intensive care unit

Neu im Fachgebiet AINS

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Leitsymptom Rückenschmerzen | Nachrichten

Ärztliche Empathie hilft gegen Rückenschmerzen

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 | Pankreaskarzinom | Nachrichten

S3-Leitlinie zu Pankreaskrebs aktualisiert
weitere anzeigen

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren